{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:07:51Z","timestamp":1792976871046,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"JSPS KAKENHI","award":["24K23360"],"award-info":[{"award-number":["24K23360"]}]},{"name":"Cancer Research Grant from the SGH Foundation"},{"name":"Translational Research Grant of Urological Oncology"},{"name":"Fukuoka Public Health Promotion Organization"},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["24lk0221196h0001"],"award-info":[{"award-number":["24lk0221196h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) tumors represent a biologically and immunologically distinct subset of solid malignancies. Defective DNA mismatch repair mechanisms in these tumors lead to the accumulation of insertion-deletion mutations, a hypermutated phenotype, and abundant tumor-specific neoantigens. These features drive robust T cell responses, explaining the remarkable sensitivity of dMMR\/MSI-H tumors to immune checkpoint inhibitors (ICIs). Emerging evidence from clinical trials across resectable dMMR\/MSI-H colorectal, gastric and gastroesophageal junction, and other solid tumors indicate that ICI therapy can induce profound pathological responses, including high rates of pathological complete response. These responses may permit organ preservation and reduce treatment-associated morbidity, offering a compelling alternative to conventional surgery-based approaches. Despite this promise, several challenges remain. Critical areas warranting further investigation include the refinement of patient selection strategies, clarification of the role of surgery in patients achieving a clinical complete response, and the identification of reliable predictive biomarkers for therapeutic response and resistance. In addition, the long-term oncologic outcomes associated with non-operative management remain to be elucidated. This review comprehensively summarizes the biological basis and emerging clinical evidence for immunotherapy in resectable dMMR\/MSI-H solid tumors. We discuss current opportunities and ongoing challenges in refining curative-intent strategies, with the aim of improving outcomes and quality of life for patients with these immunologically distinct cancers.<\/jats:p>","DOI":"10.1007\/s00262-025-04223-9","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:19:22Z","timestamp":1762431562000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Biology and evolving management of resectable dMMR\/MSI-H cancers: current status and future perspectives"],"prefix":"10.1007","volume":"74","author":[{"given":"Tokiyoshi","family":"Tanegashima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Shiota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayo","family":"Toyosaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouta","family":"Funakoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Eto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"4223_CR1","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1053\/j.gastro.2009.12.064","volume":"138","author":"CR Boland","year":"2010","unstructured":"Boland CR, Goel A (2010) Microsatellite instability in colorectal cancer. Gastroenterology 138:2073-2087.e3. https:\/\/doi.org\/10.1053\/j.gastro.2009.12.064","journal-title":"Gastroenterology"},{"key":"4223_CR2","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1038\/nm.4191","volume":"22","author":"RJ Hause","year":"2016","unstructured":"Hause RJ, Pritchard CC, Shendure J, Salipante SJ (2016) Classification and characterization of microsatellite instability across 18 cancer types. Nat Med 22:1342\u20131350. https:\/\/doi.org\/10.1038\/nm.4191","journal-title":"Nat Med"},{"key":"4223_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/2159-8290.CD-14-0863","volume":"5","author":"NJ Llosa","year":"2015","unstructured":"Llosa NJ, Cruise M, Tam A et al (2015) The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 5:43\u201351. https:\/\/doi.org\/10.1158\/2159-8290.CD-14-0863","journal-title":"Cancer Discov"},{"key":"4223_CR4","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN et al (2017) Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357:409\u2013413. https:\/\/doi.org\/10.1126\/science.aan6733","journal-title":"Science"},{"key":"4223_CR5","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1038\/s41467-022-29920-2","volume":"13","author":"BCH Lee","year":"2022","unstructured":"Lee BCH, Robinson PS, Coorens THH et al (2022) Mutational landscape of normal epithelial cells in Lynch syndrome patients. Nat Commun 13:2710. https:\/\/doi.org\/10.1038\/s41467-022-29920-2","journal-title":"Nat Commun"},{"key":"4223_CR6","first-page":"6991","volume":"61","author":"H Nakagawa","year":"2001","unstructured":"Nakagawa H, Nuovo GJ, Zervos EE et al (2001) Age-related hypermethylation of the 5 region of MLH1 in normal colonic mucosa is associated with microsatellite-unstable colorectal cancer development 1. Cancer Res 61:6991\u20136995","journal-title":"Cancer Res"},{"key":"4223_CR7","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1053\/j.gastro.2013.12.002","volume":"146","author":"AR Mensenkamp","year":"2014","unstructured":"Mensenkamp AR, Vogelaar IP, van Zelst-Stams WA et al (2014) Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors. Gastroenterology 146:643-646.e8. https:\/\/doi.org\/10.1053\/j.gastro.2013.12.002","journal-title":"Gastroenterology"},{"key":"4223_CR8","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1053\/j.gastro.2013.01.044","volume":"144","author":"M Rodr\u00edguez-Soler","year":"2013","unstructured":"Rodr\u00edguez-Soler M, P\u00e9rez-Carbonell L, Guarinos C et al (2013) Risk of cancer in cases of suspected lynch syndrome without germline mutation. Gastroenterology 144:926-e14. https:\/\/doi.org\/10.1053\/j.gastro.2013.01.044","journal-title":"Gastroenterology"},{"key":"4223_CR9","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.1002\/ijc.33115","volume":"147","author":"ME Salem","year":"2020","unstructured":"Salem ME, Bodor JN, Puccini A et al (2020) Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors. Int J Cancer 147:2948\u20132956. https:\/\/doi.org\/10.1002\/ijc.33115","journal-title":"Int J Cancer"},{"key":"4223_CR10","doi-asserted-by":"publisher","first-page":"20495","DOI":"10.1038\/s41598-022-23319-1","volume":"12","author":"YJ Kang","year":"2022","unstructured":"Kang YJ, O\u2019Haire S, Franchini F et al (2022) A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours. Sci Rep 12:20495. https:\/\/doi.org\/10.1038\/s41598-022-23319-1","journal-title":"Sci Rep"},{"key":"4223_CR11","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41571-025-01015-z","volume":"22","author":"M Ambrosini","year":"2025","unstructured":"Ambrosini M, Manca P, Nasca V et al (2025) Epidemiology, pathogenesis, biology and evolving management of MSI-H\/dMMR cancers. Nat Rev Clin Oncol 22:385\u2013407. https:\/\/doi.org\/10.1038\/s41571-025-01015-z","journal-title":"Nat Rev Clin Oncol"},{"key":"4223_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2013.00281","volume":"3","author":"A Thiel","year":"2013","unstructured":"Thiel A, Ristim\u00e4ki A (2013) Toward a molecular classification of colorectal cancer: the role of BRAF. Front Oncol 3:281. https:\/\/doi.org\/10.3389\/fonc.2013.00281","journal-title":"Front Oncol"},{"key":"4223_CR13","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U et al (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:401\u2013404. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0095","journal-title":"Cancer Discov"},{"key":"4223_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00262-012-1303-8","volume":"62","author":"K Bauer","year":"2013","unstructured":"Bauer K, Nelius N, Reuschenbach M et al (2013) T cell responses against microsatellite instability-induced frameshift peptides and influence of regulatory T cells in colorectal cancer. Cancer Immunol Immunother 62:27\u201337. https:\/\/doi.org\/10.1007\/s00262-012-1303-8","journal-title":"Cancer Immunol Immunother"},{"key":"4223_CR15","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1016\/j.cell.2020.11.004","volume":"183","author":"V Roudko","year":"2020","unstructured":"Roudko V, Bozkus CC, Orfanelli T et al (2020) Shared immunogenic poly-epitope frameshift mutations in microsatellite unstable tumors. Cell 183:1634-1649.e17. https:\/\/doi.org\/10.1016\/j.cell.2020.11.004","journal-title":"Cell"},{"key":"4223_CR16","doi-asserted-by":"publisher","unstructured":"Cancer genome atlas research network (2014) Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513:202\u2013209. https:\/\/doi.org\/10.1038\/nature13480","DOI":"10.1038\/nature13480"},{"key":"4223_CR17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nature12113","volume":"497","author":"C Kandoth","year":"2013","unstructured":"Kandoth C, Schultz N et al (2013) Integrated genomic characterization of endometrial carcinoma. Nature 497:67\u201373. https:\/\/doi.org\/10.1038\/nature12113","journal-title":"Nature"},{"key":"4223_CR18","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1158\/2159-8290.CD-17-1327","volume":"8","author":"CS Grasso","year":"2018","unstructured":"Grasso CS, Giannakis M, Wells DK et al (2018) Genetic mechanisms of immune evasion in colorectal cancer. Cancer Discov 8:730\u2013749. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-1327","journal-title":"Cancer Discov"},{"key":"4223_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176181","volume":"12","author":"LA Albacker","year":"2017","unstructured":"Albacker LA, Wu J, Smith P et al (2017) Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion. PLoS ONE 12:e0176181. https:\/\/doi.org\/10.1371\/journal.pone.0176181","journal-title":"PLoS ONE"},{"key":"4223_CR20","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1093\/jnci\/djy004","volume":"110","author":"GC Liu","year":"2018","unstructured":"Liu GC, Liu RY, Yan JP et al (2018) The heterogeneity between Lynch-associated and sporadic MMR deficiency in colorectal cancers. J Natl Cancer Inst 110:975\u2013984. https:\/\/doi.org\/10.1093\/jnci\/djy004","journal-title":"J Natl Cancer Inst"},{"key":"4223_CR21","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.3389\/fimmu.2019.03023","volume":"10","author":"NC Ramchander","year":"2020","unstructured":"Ramchander NC, Ryan NAJ, Walker TDJ et al (2020) Distinct immunological landscapes characterize inherited and sporadic mismatch repair deficient endometrial cancer. Front Immunol 10:3023. https:\/\/doi.org\/10.3389\/fimmu.2019.03023","journal-title":"Front Immunol"},{"key":"4223_CR22","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","volume":"26","author":"M Chalabi","year":"2020","unstructured":"Chalabi M, Fanchi LF, Dijkstra KK et al (2020) Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med 26:566\u2013576. https:\/\/doi.org\/10.1038\/s41591-020-0805-8","journal-title":"Nat Med"},{"key":"4223_CR23","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1056\/NEJMoa2400634","volume":"390","author":"M Chalabi","year":"2024","unstructured":"Chalabi M, Verschoor YL, Tan PB et al (2024) Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer. N Engl J Med 390:1949\u20131958. https:\/\/doi.org\/10.1056\/NEJMoa2400634","journal-title":"N Engl J Med"},{"key":"4223_CR24","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1038\/s41591-024-03250-w","volume":"30","author":"PGM de Gooyer","year":"2024","unstructured":"de Gooyer PGM, Verschoor YL, van den Dungen LDW et al (2024) Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial. Nat Med 30:3284\u20133290. https:\/\/doi.org\/10.1038\/s41591-024-03250-w","journal-title":"Nat Med"},{"key":"4223_CR25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S2468-1253(21)00348-4","volume":"7","author":"H Hu","year":"2022","unstructured":"Hu H, Kang L, Zhang J et al (2022) Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial. Lancet Gastroenterol Hepatol 7:38\u201348. https:\/\/doi.org\/10.1016\/S2468-1253(21)00348-4","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4223_CR26","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","volume":"386","author":"A Cercek","year":"2022","unstructured":"Cercek A, Lumish M, Sinopoli J et al (2022) PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med 386:2363\u20132376. https:\/\/doi.org\/10.1056\/NEJMoa2201445","journal-title":"N Engl J Med"},{"key":"4223_CR27","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1056\/NEJMoa2404512","volume":"392","author":"A Cercek","year":"2025","unstructured":"Cercek A, Foote MB, Rousseau B et al (2025) Nonoperative management of mismatch repair-deficient tumors. N Engl J Med 392:2297\u20132308. https:\/\/doi.org\/10.1056\/NEJMoa2404512","journal-title":"N Engl J Med"},{"key":"4223_CR28","doi-asserted-by":"publisher","unstructured":"Kai-Keen S,\u00a0Yanrong J,\u00a0Mark S, et al (2024) NEOPRISM-CRC: Neoadjuvant pembrolizumab stratified to tumour mutation burden for high-risk stage 2 or stage 3 deficient-MMR\/MSI-high colorectal cancer. J Clin Oncol 42:LBA3504. In: Presented at the 2024 ASCO Annual Meeting. https:\/\/doi.org\/10.1200\/JCO.2024.42.17_suppl.LBA3504","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA3504"},{"key":"4223_CR29","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1200\/JCO.22.00686","volume":"41","author":"T Andr\u00e9","year":"2023","unstructured":"Andr\u00e9 T, Tougeron D, Piessen G et al (2023) Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair\/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study. J Clin Oncol 41:255\u2013265. https:\/\/doi.org\/10.1200\/JCO.22.00686","journal-title":"J Clin Oncol"},{"key":"4223_CR30","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.annonc.2024.11.016","volume":"36","author":"A Raimondi","year":"2025","unstructured":"Raimondi A, Lonardi S, Murgioni S et al (2025) Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO. Ann Oncol 36:285\u2013296. https:\/\/doi.org\/10.1016\/j.annonc.2024.11.016","journal-title":"Ann Oncol"},{"key":"4223_CR31","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1200\/JCO.22.01351","volume":"41","author":"K Ludford","year":"2023","unstructured":"Ludford K, Ho WJ, Thomas JV et al (2023) Neoadjuvant pembrolizumab in localized microsatellite instability high\/deficient mismatch repair solid tumors. J Clin Oncol 41:2181\u20132190. https:\/\/doi.org\/10.1200\/JCO.22.01351","journal-title":"J Clin Oncol"},{"key":"4223_CR32","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s13691-025-00774-x","volume":"14","author":"K Shiraishi","year":"2025","unstructured":"Shiraishi K, Shiota M, Fukuchi G et al (2025) Complete response to pembrolizumab in mismatch repair-deficient urothelial carcinoma with local recurrence and recurrent upper tract urothelial carcinoma: a case report. Int Cancer Conf J 14:198\u2013203. https:\/\/doi.org\/10.1007\/s13691-025-00774-x","journal-title":"Int Cancer Conf J"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04223-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04223-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04223-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:45:36Z","timestamp":1764600336000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04223-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":32,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4223"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04223-9","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"assertion":[{"value":"25 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MS received honoraria from Janssen Pharmaceutical, AstraZeneca, Astellas Pharma, Sanofi and Bayer Yakuhin and research funding support from Astellas Pharma. ME received honoraria from Ono Pharmaceutical, Takeda Pharmaceutical, Novartis Pharma, Pfizer, Bristol-Myers Squibb, Janssen Pharmaceutical, MSD, Merck Biopharma, AstraZeneca and Eisai, and research funding support from Bayer Yakuhin, Astellas Pharma, Ono Pharmaceutical and Takeda Pharmaceutical.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"364"}}